Tauseef Akhtar
Cardiovascular Disease · Mason City, IANPI 1508218009
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (44.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Abbott at 54.3% of the total. 2025 is the largest year on record at $4,918, more than ten times the $441 reported in 2022.
Across 109 payments — averaging $70.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$959
- AstraZeneca$533
- Boston Scientific$277
- Shockwave Medical, Inc$275
- Actelion Pharmaceuticals US, Inc.$268
- plus $1K from 15 others
What the payments were for
- Travel & lodging$3,39044%
- Food & beverage$2,97839%
- Education$1,28617%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 40 | $4,160 |
| Medtronic | 14 | $959 |
| AstraZeneca | 11 | $533 |
| Boston Scientific | 3 | $277 |
| Shockwave Medical, Inc | 1 | $275 |
| Actelion Pharmaceuticals US, Inc. | 4 | $268 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $259 |
| Abiomed | 2 | $217 |
| Penumbra, Inc. | 1 | $143 |
| E.r. Squibb & Sons, L.L.C. | 5 | $97 |
| Janssen Scientific Affairs, LLC | 1 | $79 |
| Boehringer Ingelheim | 4 | $74 |
| Novartis | 3 | $72 |
| Teleflex LLC | 1 | $65 |
| Getinge USA Sales, LLC | 2 | $48 |
| Merck | 1 | $42 |
| Biosense Webster, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $19 |
| Cook Medical LLC | 1 | $15 |
| Asahi Intecc USA, Inc. | 1 | $15 |
| Terumo Medical Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,655 in reported general payments places this provider in the 85th percentile of 142 cardiovascular disease providers in Iowa.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 31 | $24,942 |
| Metoprolol Succinate | 77 | $775 |
| Torsemide | 13 | $439 |
| Atorvastatin Calcium | 39 | $287 |
| Nitroglycerin | 15 | $181 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 16 | $161 |
| ClopidogrelClopidogrel Bisulfate | 24 | $148 |
| Lisinopril | 31 | $131 |
| Allopurinol | 21 | $128 |
| Memantine Hcl | 21 | $118 |
| Losartan Potassium | 18 | $84 |
| Hydrochlorothiazide | 21 | $81 |
| Carvedilol | 14 | $79 |
| Metoprolol Tartrate | 12 | $64 |
| Furosemide | 14 | $59 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Mason City
- Sepideh DarbandiMason City$9K
- Noor SubahMason City$8K
- Michael SpoonerMason City$7K
- Radu HagauMason City$3K
- Brett CarlsonMason City$2K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.